Up-titration of allopurinol in patients with gout

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 1, 2014, Pages 25-30

  Jennings, Claudine G ^a   Mackenzie, Isla S ^a   Flynn, Rob ^a   Ford, Ian ^b,e   Nuki, George ^c,e   De Caterina, Raffaele ^d,e   Riches, Philip L ^c   Ralston, Stuart H ^c,e   MacDonald, Thomas M ^a   Mackenzie, Isla ^a,e   MacDonald, Thomas ^a,e   Findlay, Evelyn ^e   Hallas, Jesper ^f,i   Hawkey, Chris ^f,j   Walters, Matthew ^b,f   Webster, John ^f,h   McMurray, John ^f   Ruiz, Fernando Perez ^g   Riches, Philip ^c   Harvie, John ^k  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF CHIETI   (Italy)

^e Medicines Monitoring Unit (MEMO)   (United Kingdom)

^f Heumatology Consultant ^*

^g Heumatology Consultant   (Spain)

^h ABERDEEN ROYAL INFIRMARY   (United Kingdom)

ⁱ UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^j UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^k RAIGMORE HOSPITAL   (United Kingdom)

more..

Author keywords

Allopurinol; Clinical guidelines; Gout; Prescribing

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; NONSTEROID ANTIINFLAMMATORY AGENT; URATE; ANTIGOUT AGENT;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GOUT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL; AGED; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED;

AGED; ALLOPURINOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED;

EID: 84905224562     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.01.004     Document Type: Article

References (21)

1. Annemans L., Spaepen E., Gaskin M., Bonnemaire M., Malier V., Gilbert T., et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008, 67:960-966.
2. Roddy E., Zhang W., Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol 2007, 3:443-449.
3. Elliot A.J., Cross K.W., Fleming D.M. Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994-2007. Ann Rheum Dis 2009, 68:1728-1733.
4. Office of national statistics. National population projections, 〈〉 2012 [accessed May 2013]. http://www.ons.gov.uk/ons/rel/npp/national-population-projections/2010-based-reference-volume--series-pp2/results.html%23tab-Age-structure.
5. Zhang W., Doherty M., Bardin T., Pascual E., Barskova V., Conaghan P., et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324.
6. Khanna D., Fitzgerald J.D., Khanna P.P., Bae S., Singh M.K., Neogi T., et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012, 64:1431-1446.
7. Mikuls T.R., Farrar J.T., Bilker W.B., Fernandes S., Schumacher H.R., Saag K.G. Gout epidemiology: results from the UK general practice research database, 1990-1999. Ann Rheum Dis 2005, 64:267-272.
8. Roddy E., Zhang W.Y., Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis 2007, 66:1311-1315.
9. Rashid N., Cheetham T.C., Curtis J.R., Levy G.D., Saag K.G., Mikuls T.R. Gout treatment gaps and factors associated with incident patients having uric acid goal attainment: a retrospective cohort study in an integrated healthcare system. Arthritis Rheum 2011, 63:S349.
10. Roberts C., Adebajo A.O., Long S. Improving the quality of care of musculoskeletal conditions in primary care. Rheumatology 2002, 41:503-508.
11. Schumacher H.R., Becker M.A., Wortmann R.L., MacDonald P.A., Hunt B., Streit J., et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthrit Care Res 2008, 59:1540-1548.
12. Becker M.A., Schumacher H.R., Wortmann R.L., MacDonald P.A., Eustace D., Palo W.A., et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353:2450-2461.
13. Jordan K.M., Cameron J.S., Snaith M., Zhang W., Doherty M., Seckl J.R., et al. British Society for Rheumatology and British Health Professionals in rheumatology guideline for the management of gout. Rheumatology 2007, 46:1372-1374.
14. Doherty M., Jansen T.L., Nuki G., Pascual E., Perez-Ruiz F., Punzi L., et al. Gout: why is this curable disease so seldom cured?. Ann Rheum Dis 2012, 71:1765-1770.
15. Rees F., Jenkins W., Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis 2013, 72:826-830.
16. Pal B., Foxall M., Dysart T., Carey F., Whittaker M. How is gout managed in primary care? A review of current practice and proposed guidelines. Clin Rheumatol 2000, 19:21-25.
17. Stamp L.K., Taylor W.J., Jones P.B., Dockerty J.L., Drake J., Frampton C., et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012, 64:2529-2536.
18. Datapharm. Electronic Medicines Compendium, 〈〉 2013 [accessed May 2013]. http://www.medicines.org.uk/emc/medicine/23722/SPC.
19. Stamp L.K., Taylor W., Jones P.B.B., Dockerty J.L., Drake J., Frampton C., et al. Starting dose, but not maximum maintenance dose, is a risk factor for allopurinol hypersensitivity syndrome: a proposed nomogram for safe starting dosing of allopurinol. Arthritis Rheum 2012, 63:S1012.
20. Jung J.W., Song W.J., Kim Y.S., Joo K.W., Lee K.W., Kim S.H., et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant 2011, 26:3567-3572.
21. Hande K., Noone R., Stone W. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984, 76:47-56.